AbbVie and Umoja Biopharma announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology.
AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform. The first agreement provides AbbVie an exclusive…